National plaintiffs' law firm Berger Montague PCannounces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period ofFebruary 21, 2025 through August 28, 2025 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline: Investors who purchased Telixsecurities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE.
Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company developing diagnostic and therapeutic radiopharmaceutical products.
During the Class Period, defendants allegedly made false or misleading statements and/or failed to disclose that the Company had overstated its progress with prostate cancer therapeutic candidates and exaggerated the quality of its supply chain and partners. As a result, statements regarding the Company's business, operations, and prospects were allegedly false, misleading, or lacked a reasonable basis. According to the complaint, when the true state of the Telix's business became public, investors suffered significant losses.
If you are a Telix investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigationsince its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:Andrew AbramowitzSenior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniDirector of Portfolio & Institutional Client Monitoring ServicesBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC22746&sd=2025-11-12
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-telix-pharmaceuticals-ltd-nasdaq-tlx-after-class-action-filing-302613242.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC22746&Transmission_Id=202511121303PR_NEWS_USPR_____DC22746&DateId=20251112